Can you take Betrixaban with Treprostinil?

Betrixaban has a moderate potential interaction with Antiphospholipid syndrome.

Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS). Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.

Treprostinil has a moderate potential interaction with Bleeding Associated with Coagulation Defect.

Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding. Close monitoring is recommended when using this agent in patients with bleeding disorders.

Betrixaban has a major potential interaction with Bleeding Disorder.

The use of betrixaban is contraindicated in patients with active pathological bleeding. Care and close monitoring is recommended when using this agent in patients who are receiving neuraxial anesthesia or undergoing spinal puncture as epidural or spinal hematomas may occur. Consider risk of using this agent when scheduling patients for spinal procedures.

Treprostinil has a moderate potential interaction with Diverticulitis.

The tablet shell of the manufactured form of treprostinil, Orenitram does not dissolve and can lodge in the diverticulum of patients with diverticulosis. Care should be exercised when using this drug in patient with diverticulosis.

Treprostinil has a moderate potential interaction with Hypotension.

Treprostinil is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with treprostinil injection may produce symptomatic hypotension. Care should be exercised when using this agent in patients at risk.

Betrixaban has a major potential interaction with Liver Disease.

The use of betrixaban is not recommended in patients with hepatic impairment as these patients may have intrinsic coagulation abnormalities.

Treprostinil has a major potential interaction with Liver Disease.

The use of the extended-release tablet formulation of treprostinil is contraindicated in patients with severe hepatic impairment (Child Pugh Class C). There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients. It is recommended to start patients with mild hepatic impairment (Child Pugh Class A) at 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days and to avoid use of treprostinil in patients with moderate hepatic impairment (Child Pugh Class B).

Treprostinil has a moderate potential interaction with Liver Disease.

Severe hepatic impairment (Child Pugh Class C) is a contraindication in patients taking the oral presentation of treprostinil. Treprostinil is substantially metabolized by the liver, primarily by CYP450 2C8. Treprostinil injection clearance is reduced in patients with hepatic insufficiency. In patients with mild or moderate hepatic insufficiency, decrease the initial dose of treprostinil injection to 0.625 ng/kg/min ideal body weight, and monitor closely. Treprostinil injection has not been studied in patients with severe hepatic insufficiency. It is recommended to titrate treprostinil injection slowly in patients with hepatic insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.

Treprostinil has a moderate potential interaction with Pulmonary Impairment.

The efficacy of treprostinil inhalant has not been established in patients with significant underlying lung disease. Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect.

Betrixaban has a major potential interaction with Renal Dysfunction.

Patients with severe renal impairment (CrCl >= 15 to < 30 mL/min computed by Cockcroft-Gault using actual body weight) may have an increased risk of bleeding events. It is recommended to reduce the betrixaban dose in patients with severe renal impairment. Monitor patients closely and promptly evaluate any signs or symptoms of blood loss in these patients. No dose adjustment is needed for mild or moderate renal impairment (CrCl > 30 mL/min, computed by Cockcroft-Gault using actual body weight).

Treprostinil has a moderate potential interaction with Renal Dysfunction.

Treprostinil and its metabolites are excreted mainly through the urinary route. It is recommended to titrate treprostinil injection slowly in patients with renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal renal function. No dose adjustments are required in patients with renal impairment. Treprostinil is not cleared by dialysis.